A Meta-analysis to Assess the FDA DAVP’s TLOVR Algorithm in HIV Submissions
- 1 May 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drug Information Journal
- Vol. 45 (3), 291-300
- https://doi.org/10.1177/009286151104500309
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trialThe Lancet, 2006
- Abacavir versus Zidovudine Combined with Lamivudine and Efavirenz, for the Treatment of Antiretroviral‐Naive HIV‐Infected AdultsClinical Infectious Diseases, 2004
- The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugsAIDS, 1999
- Surrogate Endpoints in Aids Drug Development: Current StatusDrug Information Journal, 1998
- Use of Changes in Plasma Levels of Human Immunodeficiency Virus Type 1 RNA to Assess the Clinical Benefit of Antiretroviral TherapyThe Journal of Infectious Diseases, 1998